KIT and gastrointestinal stromal tumor: Additionally, the selective KIT-mutant inhibitor AZD3229, which was discovered by AstraZeneca (29) and was licensed as NB003 to NingBo Newbay Technologies, recently started a phase I study in patients with advanced solid tumors, including GIST (30).